Wouldn’t it be nice to replace your diseased or aging organs with a brand new one made from your own stem cells? Science fiction has dreamed of this future, but only in the last few years, this is beginning to become a reality. Many promising technologies, like induced pluripotent stem cells (iPSC) and cell grafting, are creating new options for desperate patients.
Come hear the latest in tissue engineering and regenerative medicine from 3 companies in the field, as well as what challenges lie ahead. Drinks and light food will be served.
Ryan Bonvillain, Tissue Engineering Scientist at United Therapeutics (http://www.unither.com/)
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. We have five approved products on the market today and are relentless in our pursuit of “medicines for life”®.
Nicholas Pashos, CEO of BioAesthetics (http://bio-aesthetics.com)
BioAesthetics is regenerating the nipple-areolar complex for the 200,000+ women whom undergo mastectomies every year.
Drew Titmarsh, CEO of Scaled Biolabs (http://scaledbiolabs.com/)
Scaled Biolabs is accelerating biologic, gene, and cell therapies using smart microfluidic chips. Thousands of cell experiments can be parallelized and automated on their lab-on-a-chip system, increasing throughput, precision, economy, and insight that can lead to dramatic innovations in organogenesis, fermentation condition optimization and therapeutic production.
Ken Nogami, Co-CEO of Metcela (https://www.metcela.com)
Metcela Inc. is a pioneer regenerative medicine company founded in Japan. Metcela aims to be the first to commercialize fibroblast-based biological products that heal damaged heart muscle and treat heart failure.